# Legend Biotech USA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/legend-biotech-usa

- Industry: Biotechnology
- Headquarters: Somerset, US
- Website: www.legendbiotech.com
- Total disclosed funding: $151M
- Latest round: Series A (Mar 30, 2020)
- Investors on record: 5

## About

Founded in 2014 and based in New Jersey, US, Legend Biotech USA, Inc. is a biotech company that focuses on the development of tumor cell immunotherapy. In 2020, the company was listed on the NASDAQ. Its ticker symbol is LEGN. In May 2023, Hillhouse Capital Group invested in Legend Biotech USA, Inc. for USD 12.7 million. Ying Huang, the company's CEO, also serves as a board member of the company and Quanta Therapeutics. He has more than 9 years of R&D background in large multinational pharmaceutical companies and 12 years of experience as a biotech analyst on Wall Street. In May 2023, returning investor Hillhouse Capital Group invested in Legend Biotech USA, Inc. for USD 22.2 million.

The company's R&D pipeline mainly includes small cell lung cancer DLL3, multiple myeloma BCMA and hepatocellular carcinoma GPC3, etc. It has developed CAR-T therapy targeting CD38 and BCMA for the treatment of multiple myeloma. Its products are used to treat diseases such as blood cancers and lymphomas.

## Funding rounds

- Series A, Mar 30, 2020, $151M — Johnson & Johnson Innovation, Vivo Capital, Lilly Asia Ventures, Hudson Bay Capital, RA Capital Management

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Hudson Bay Capital — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A